Cargando…

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19

Detalles Bibliográficos
Autores principales:	Seo, Hyeonji, Chong, Yong Pil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259909/ https://www.ncbi.nlm.nih.gov/pubmed/35794721 http://dx.doi.org/10.3947/ic.2022.0045

Ejemplares similares

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
por: Seo, Hyeonji, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Reply to correspondence “Contributing factors towards progression of migraines during the Covid-19 pandemic”
por: Yuksel, Hatice, et al.
Publicado: (2022)

Correspondence: Reply to ‘Phantom phonon localization in relaxors’
por: Manley, Michael E., et al.
Publicado: (2017)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Correspondence: Reply to: ‘Correspondence: Variations in ocean heat uptake during the surface warming hiatus'
por: Liu, Wei, et al.
Publicado: (2016)

Reply to the correspondence to the “Guideline for acute therapy and management of anaphylaxis”
por: Ring, Johannes
Publicado: (2015)

Correspondence: Reply to ‘On the bonding in ligand-protected gold clusters’
por: Xu, Wen Wu, et al.
Publicado: (2017)

Correspondence: Reply to ‘Chimpanzee helping is real, not a byproduct’
por: Jensen, Keith, et al.
Publicado: (2018)

Correspondence: Reply to ‘DNA shape is insufficient to explain binding'
por: Kasinathan, Sivakanthan, et al.
Publicado: (2017)

Correspondence and Reply of Dr. W. Mitchell
Publicado: (1892)

Correspondence (reply): The application conditions of false discovery rate control
por: Zhang, Hongbin, et al.
Publicado: (2022)

Correspondence: Reply to ‘The experimental requirements for a photon thermal diode’
por: Chen, Zhen, et al.
Publicado: (2017)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Correspondence: Reply to ‘Space-time asymmetry undermines water yield assessment'
por: Chen, Xiuzhi, et al.
Publicado: (2016)

Correspondence: Reply to ‘On the nature of strong piezoelectricity in graphene on SiO(2)'
por: da Cunha Rodrigues, Gonçalo, et al.
Publicado: (2016)

Correspondence: Reply to ‘SEMA4A variation and risk of colorectal cancer'
por: Sill, Heinz, et al.
Publicado: (2016)

Correspondence: Reply to ‘Challenges with dating weathering products to unravel ancient landscapes’
por: Fredin, Ola, et al.
Publicado: (2017)

Correspondence: Reply to ‘Revisiting the theoretical cell membrane thermal capacitance response’
por: Shapiro, Mikhail G., et al.
Publicado: (2017)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Correspondence: Reply to ‘Numerical modelling of the PERM anomaly and the Emeishan large igneous province’
por: Flament, N., et al.
Publicado: (2017)

Long-COVID-19 patients and sleep disorders: correspondence
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Erratum: Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
Publicado: (2022)

Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
por: Murakami, Naoka, et al.
Publicado: (2023)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2021)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

Reply to: COVID-19 and Coagulopathy
por: Rodríguez, Cristina, et al.
Publicado: (2021)

COVID-19 Pandemic: The Way Forward – Correspondence
por: Vijayasekaran, D., et al.
Publicado: (2020)

Correspondence: Reply to ‘Quantitative evaluation of X-ray dark-field images for microcalcification analysis in mammography'
por: Wang, Zhentian, et al.
Publicado: (2016)

Correspondence: Reply to ‘Challenging a proposed role for TRPC5 in aortic baroreceptor pressure-sensing’
por: Lau, On-Chai, et al.
Publicado: (2018)

Thanks and reply from the editors of the ABD to the comments on the correspondence sent to heads of services accredited by SBD
por: Talhari, Sinésio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r18rs0mia1sugqe1ihci8p59bb